InflaRx Announces Pricing of Initial Public Offering

In addition, InflaRx has granted the underwriters a 30-day greenshoe option to purchase up to 1,000,050 additional common shares at the public offering price. The shares are scheduled to begin trading on the NASDAQ Global Select Market on November 8, 2017 under the ticker symbol "IFRX." J.P. Morgan, Leerink Partners and BMO Capital Markets are acting as joint book-running managers for the offering.

InflaRx has two first-in-class blockers of complement factor C5a, the essential component in terminal complement activation, which boosts inflammation, in its pipeline. IFX-1, a novel intravenously administered first-in-class anti-C5a monoclonal antibody is being tested in Phase II clinical trails for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease. The antibody is in Phase I testing for ANCA-associated vasculitis, a rare and life-threatening autoimmune disease, and other chronic/autoimmune diseases. In October Inflarx closed a Series D financing to fund further developement of its lead compound and announced its intention to float to Nasdaq. The company’s preclinical C5a inhibitor IFX-2 target chronic inflammation-related diseases.